WILMINGTON, Del., April 14, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)?
- Did you purchase your shares between May 6, 2014 and February 23, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of PTC Therapeutics (“PTC” or the “Company”) (NASDAQ:PTCT) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the District of New Jersey on behalf of all persons or entities that purchased the common stock of PTC between May 6, 2014 and February 23, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than May 2, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of PTC during the Class Period, or purchased shares prior to the Class Period and still hold PTC, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to info@rl-legal.com; or at: http://rigrodskylong.com/investigations/ptc-therapeutics-inc-ptct.
Attorney advertising. Prior results do not guarantee a similar outcome.